DiaMedica Therapeutics Inc. (DMAC) stock
DMACNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.66−0.01 (-0.10%)
Close on Nov 11, 2026Market cap $520.92MP/E –Yield –
DiaMedica Therapeutics total assets
Total assets on the balance sheet at the end of each period.
DiaMedica Therapeutics's total assets was $36.15M at Sep 30, 2026. For fiscal 2025 it was $61.37M, up 32.4% from the year before. The highest annual figure on record is $61.37M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.37M | +32.4% |
| FY2024 | Dec 31, 2024 | $46.35M | -14.4% |
| FY2023 | Dec 31, 2023 | $54.16M | +57.5% |
| FY2022 | Dec 31, 2022 | $34.40M | -24.5% |
| FY2021 | Dec 31, 2021 | $45.55M | +62.1% |
| FY2020 | Dec 31, 2020 | $28.10M | +210.3% |
| FY2019 | Dec 31, 2019 | $9.05M | -50.6% |
| FY2018 | Dec 31, 2018 | $18.34M | +917.7% |
| FY2017 | Dec 31, 2017 | $1.80M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $36.15M | -36.6% |
| Q2 FY2026 | Jun 30, 2026 | $45.00M | +43.0% |
| Q1 FY2026 | Mar 31, 2026 | $53.08M | +36.7% |
| Q4 FY2025 | Dec 31, 2025 | $61.37M | +32.4% |
| Q3 FY2025 | Sep 30, 2025 | $57.05M | +8.6% |
| Q2 FY2025 | Jun 30, 2025 | $31.47M | -44.6% |
| Q1 FY2025 | Mar 31, 2025 | $38.83M | -21.2% |
| Q4 FY2024 | Dec 31, 2024 | $46.35M | -14.4% |
| Q3 FY2024 | Sep 30, 2024 | $52.52M | -9.7% |
| Q2 FY2024 | Jun 30, 2024 | $56.79M | -8.5% |
| Q1 FY2024 | Mar 31, 2024 | $49.26M | +63.0% |
| Q4 FY2023 | Dec 31, 2023 | $54.16M | +57.5% |
| Q3 FY2023 | Sep 30, 2023 | $58.14M | +57.0% |
| Q2 FY2023 | Jun 30, 2023 | $62.05M | +58.1% |
| Q1 FY2023 | Mar 31, 2023 | $30.22M | -28.4% |
| Q4 FY2022 | Dec 31, 2022 | $34.40M | -24.5% |
| Q3 FY2022 | Sep 30, 2022 | $37.04M | -23.9% |
| Q2 FY2022 | Jun 30, 2022 | $39.26M | +80.3% |
| Q1 FY2022 | Mar 31, 2022 | $42.21M | +73.3% |
| Q4 FY2021 | Dec 31, 2021 | $45.55M | +62.1% |
| Q3 FY2021 | Sep 30, 2021 | $48.66M | +55.6% |
| Q2 FY2021 | Jun 30, 2021 | $21.77M | +73.1% |
| Q1 FY2021 | Mar 31, 2021 | $24.36M | +69.6% |
| Q4 FY2020 | Dec 31, 2020 | $28.10M | +210.3% |
| Q3 FY2020 | Sep 30, 2020 | $31.27M | +183.3% |
| Q2 FY2020 | Jun 30, 2020 | $12.58M | -1.7% |
| Q1 FY2020 | Mar 31, 2020 | $14.37M | -7.3% |
| Q4 FY2019 | Dec 31, 2019 | $9.05M | -50.6% |
| Q3 FY2019 | Sep 30, 2019 | $11.04M | +512.6% |
| Q2 FY2019 | Jun 30, 2019 | $12.80M | – |
| Q1 FY2019 | Mar 31, 2019 | $15.49M | – |
| Q4 FY2018 | Dec 31, 2018 | $18.34M | – |
| Q4 FY2017 | Dec 31, 2017 | $1.80M | – |
See a number that looks wrong?